Anti-Rabies Serum Market Report 2026

Anti-Rabies Serum Market Overview

• Anti-Rabies Serum market size has reached to $1.5 billion in 2025 • Expected to grow to $1.95 billion in 2030 at a compound annual growth rate (CAGR) of 5.3% • Growth Driver: The Rise In The Prevalence Of Dog Bites Propelling The Growth Of The Anti-Rabies Serum Market • Market Trend: Biopharmaceutical Partnership Aims To Prevent Rabies And Raise Disease Awareness In The US • North America was the largest region in 2025.

What Is Covered Under Anti-Rabies Serum Market?

Anti-rabies serum, also known as rabies immune globulin (RIG), refers to a medical treatment used to provide immediate passive immunity against the rabies virus. It is administered to individuals who have been exposed to the virus through bites or scratches from potentially rabid animals, typically in conjunction with the rabies vaccine. The serum contains antibodies that neutralize the virus, helping to prevent the onset of rabies, which is a fatal disease once symptoms appear. The main types of anti-rabies serum are human anti-rabies immunoglobulin and equine anti-rabies immunoglobulin. Human rabies immune globulin (HRIG) is derived from the blood plasma of human donors who have been immunized against rabies. It is preferred due to its reduced risk of allergic reactions and compatibility with human patients. These serum comes in various dosage forms, including vials and prefilled syringes, and is administered through intravenous and intramuscular. These are used by many end-users, including hospitals, clinics, and veterinary hospitals.

What Is The Anti-Rabies Serum Market Growth Forecast?

The anti-rabies serum market size is expected to see strong growth in the next few years. It will grow to $1.95 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing adoption of human anti-rabies immunoglobulin, expansion of rabies prevention initiatives in developing regions, rising investments in biologics manufacturing, growing focus on safer serum alternatives, strengthening public health vaccination frameworks. Major trends in the forecast period include increasing adoption of human-derived immunoglobulins, rising preference for prefilled syringe formats, expansion of cold-chain optimized serum distribution, growing focus on high-purity antibody formulations, improved standardization of post-exposure prophylaxis protocols.

Global Anti-Rabies Serum Market Segmentation

1) By Type: Human Anti-rabies Immunoglobulin, Equine Anti-rabies Immunoglobulin 2) By Dosage And Form: Vials, Prefilled Syringes 3) By Route of Administration: Intravenous, Intramuscular 4) By End User: Hospitals, Clinics, Veterinary Hospitals Subsegments: 1) By Human Anti-Rabies Immunoglobulin: Monovalent Human Anti-Rabies Immunoglobulin, Polyvalent Human Anti-Rabies Immunoglobulin, Intramuscular Human Anti-Rabies Immunoglobulin, Intravenous Human Anti-Rabies Immunoglobulin, Freeze-Dried Human Anti-Rabies Immunoglobulin 2) By Equine Anti-Rabies Immunoglobulin: Freeze-Dried Equine Anti-Rabies Immunoglobulin, Liquid Equine Anti-Rabies Immunoglobulin, Monovalent Equine Anti-Rabies Immunoglobulin, Polyvalent Equine Anti-Rabies Immunoglobulin

What Is The Driver Of The Anti-Rabies Serum Market?

The rise in the prevalence of dog bites is expected to propel the growth of the anti-rabies serum market going forward. Dog bites refer to injuries caused when a dog bites or scratches a person, which can vary from minor to severe. These bites can lead to infections, serious wounds, and, in some cases, transmission of diseases such as rabies. Effective prevention and prompt medical treatment are crucial for managing and mitigating the risks associated with dog bites. The rise in the prevalence of dog bites is due to several factors, such as increased urbanization leading to more frequent interactions between people and dogs, a higher number of unrestrained or poorly trained dogs, and insufficient awareness or education about dog behavior and bite prevention. The rise in the prevalence of dog bites has led to increased demand for anti-rabies serum, as timely administration of the serum is crucial for preventing the onset of rabies in individuals exposed to potentially infected animals. For instance, in 2023, according to the American Veterinary Medical Association, a US-based non-profit organization, the average cost for dog bite insurance claims in 2023 was $58,545. Insurers paid out $1.12B in liability claims related to dog bites and other dog-related injuries in 2023. Dog bite claims increased by nearly 10% in 2023. Therefore, the rise in the prevalence of dog bites is driving the growth of the anti-rabies serum industry.

Key Players In The Global Anti-Rabies Serum Market

Major companies operating in the anti-rabies serum market are Merck & Co Inc., Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, HCX Pharmaceuticals LLP, Intas Pharmaceuticals Ltd, Bavarian Nordic AS, Serum Institute of India Pvt Ltd., Bharat Serums And Vaccines Limited, Indian Immunologicals Ltd., Bharat Biotech., National Institute of Health Islamabad, ViNS Bioproducts Ltd., Shanghai Serum Bio-technology, Premium Serums and Vaccines Pvt Ltd., Congruent Pharmachem, Haffkine Bio Pharmaceutical Corporation Limited, LEXICARE PHARMA PVT. LTD., Avin Darou, Central Research Institute Kasauli, Vigilomed Pharmaceuticals

Global Anti-Rabies Serum Market Trends and Insights

Major companies in the anti-rabies serum market are adopting strategic partnerships to enhance product development and expand market reach. Strategic partnerships refer to a process in which companies leverage each other's strengths and resources to achieve mutual benefits and success. For instance, in July 2023, Kedrion S.p.A., a US-based biopharmaceutical company, partnered with Kamada, an Israel-based biopharmaceutical company, to distribute KEDRAB (Rabies Immune Globulin [Human]) in the US. This collaboration has been instrumental in co-developing and licensing the product in the U.S., while also raising disease awareness. Through their efforts, the partnership has helped protect individuals exposed to rabid animal bites from serious and potentially life-threatening conditions.

What Are Latest Mergers And Acquisitions In The Anti-Rabies Serum Market?

In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical company that develops, manufactures, and commercializes plasma-derived therapeutic products, executed a binding memorandum of understanding with Kamada Ltd to extend and strengthen their collaboration for the human rabies immune globulin product KEDRAB. With this partnership, Kedrion and Kamada aim to secure long-term supply, enhance commercial reach, and expand market opportunities in rabies prophylaxis. Kamada Ltd. is an Israel-based biopharmaceutical company specializing in plasma-derived protein therapeutics.

Regional Insights

North America was the largest region in the anti-rabies serum market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anti-Rabies Serum Market?

The anti-rabies serum market consists of sales of rabies monoclonal antibodies, rabies immune globulin (RIG) combination products, and human rabies immune globulin (HRIG). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anti-Rabies Serum Market Report 2026?

The anti-rabies serum market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-rabies serum industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.